TY - JOUR
T1 - Advances in diagnosing peanut allergy
AU - Sicherer, Scott H.
AU - Wood, Robert A.
N1 - Funding Information:
Conflicts of interest: S. H. Sicherer has received consultancy fees from the Food Allergy Initiative and is on the Food Allergy and Anaphylaxis Network Medical Advisory Board. R. A. Wood has received consultancy fees from the Asthma and Allergy Foundation of America; is employed by Johns Hopkins University; has provided expert testimony for the National Institutes of Health; and receives royalties from UpToDate.
PY - 2013/1
Y1 - 2013/1
N2 - Peanut allergy is often severe, potentially fatal, usually persistent, and appears to have increased in prevalence. An accurate diagnosis is essential because there is a significant burden on quality of life. The tools available for diagnosis include the medical history, skin prick test (SPT), determination of serum peanut-specific IgE antibodies (PN-IgE), and medically supervised oral food challenges. Numerous studies, almost exclusively in children, have correlated clinical outcomes against SPTs and PN-IgE with informative results. The diagnostic utility of SPT and PN-IgE is maximized by considering the degree of positive result and consideration of the medical history (a priori estimation of risk). Emerging tests that evaluate IgE binding to specific proteins in peanut (component testing) add important additional diagnostic information in specific settings. Studies are increasingly focused on how the results of tests considered in combination (or performed serially) may increase diagnostic accuracy. Here, we review the utility of currently available tests and provide suggestions on how to best use them to accurately predict peanut allergy. Still, the physician-supervised oral food challenge remains the most definitive test available.
AB - Peanut allergy is often severe, potentially fatal, usually persistent, and appears to have increased in prevalence. An accurate diagnosis is essential because there is a significant burden on quality of life. The tools available for diagnosis include the medical history, skin prick test (SPT), determination of serum peanut-specific IgE antibodies (PN-IgE), and medically supervised oral food challenges. Numerous studies, almost exclusively in children, have correlated clinical outcomes against SPTs and PN-IgE with informative results. The diagnostic utility of SPT and PN-IgE is maximized by considering the degree of positive result and consideration of the medical history (a priori estimation of risk). Emerging tests that evaluate IgE binding to specific proteins in peanut (component testing) add important additional diagnostic information in specific settings. Studies are increasingly focused on how the results of tests considered in combination (or performed serially) may increase diagnostic accuracy. Here, we review the utility of currently available tests and provide suggestions on how to best use them to accurately predict peanut allergy. Still, the physician-supervised oral food challenge remains the most definitive test available.
KW - Component-resolved diagnosis
KW - Diagnosis
KW - Likelihood ratio
KW - Peanut allergy
KW - Predictive value
KW - Skin prick test
KW - Specific IgE testing
UR - http://www.scopus.com/inward/record.url?scp=84877992250&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2012.10.004
DO - 10.1016/j.jaip.2012.10.004
M3 - Review article
C2 - 24229816
AN - SCOPUS:84877992250
SN - 2213-2198
VL - 1
SP - 1
EP - 13
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 1
ER -